Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in First-line Newly Diagnosed CML-CP
NCT04925141Phase 4Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2016; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04925141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925141.